These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer's disease mouse model. Fol R; Braudeau J; Ludewig S; Abel T; Weyer SW; Roederer JP; Brod F; Audrain M; Bemelmans AP; Buchholz CJ; Korte M; Cartier N; Müller UC Acta Neuropathol; 2016 Feb; 131(2):247-266. PubMed ID: 26538149 [TBL] [Abstract][Full Text] [Related]
6. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42). Rockenstein E; Mallory M; Mante M; Sisk A; Masliaha E J Neurosci Res; 2001 Nov; 66(4):573-82. PubMed ID: 11746377 [TBL] [Abstract][Full Text] [Related]
7. Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice. Fragkouli A; Tsilibary EC; Tzinia AK Neurobiol Dis; 2014 Oct; 70():179-89. PubMed ID: 25008761 [TBL] [Abstract][Full Text] [Related]
8. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library. Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663 [TBL] [Abstract][Full Text] [Related]
9. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease. Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117 [TBL] [Abstract][Full Text] [Related]
10. [Pathogenesis of Alzheimer's disease: molecular and cellular mechanisms]. Govaerts L; Schoenen J; Bouhy D Rev Med Liege; 2007 Apr; 62(4):209-16. PubMed ID: 17566391 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates. Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902 [TBL] [Abstract][Full Text] [Related]
12. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease. Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867 [TBL] [Abstract][Full Text] [Related]
13. The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. Rockenstein E; Adame A; Mante M; Moessler H; Windisch M; Masliah E J Neural Transm (Vienna); 2003 Nov; 110(11):1313-27. PubMed ID: 14628195 [TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cells. Chen LM; Lin ZY; Zhu YG; Lin N; Zhang J; Pan XD; Chen XC Eur J Pharmacol; 2012 Jan; 675(1-3):15-21. PubMed ID: 22166376 [TBL] [Abstract][Full Text] [Related]
15. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models. Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932 [TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. Stumm C; Hiebel C; Hanstein R; Purrio M; Nagel H; Conrad A; Lutz B; Behl C; Clement AB Neurobiol Aging; 2013 Nov; 34(11):2574-84. PubMed ID: 23838176 [TBL] [Abstract][Full Text] [Related]
17. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. Qing H; He G; Ly PT; Fox CJ; Staufenbiel M; Cai F; Zhang Z; Wei S; Sun X; Chen CH; Zhou W; Wang K; Song W J Exp Med; 2008 Nov; 205(12):2781-9. PubMed ID: 18955571 [TBL] [Abstract][Full Text] [Related]
18. Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model. Durairajan SS; Liu LF; Lu JH; Chen LL; Yuan Q; Chung SK; Huang L; Li XS; Huang JD; Li M Neurobiol Aging; 2012 Dec; 33(12):2903-19. PubMed ID: 22459600 [TBL] [Abstract][Full Text] [Related]
19. Transcriptional and post-transcriptional regulation of β-secretase. Tamagno E; Guglielmotto M; Monteleone D; Vercelli A; Tabaton M IUBMB Life; 2012 Dec; 64(12):943-50. PubMed ID: 23180460 [TBL] [Abstract][Full Text] [Related]
20. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools. Mitani Y; Yarimizu J; Akashiba H; Shitaka Y; Ni K; Matsuoka N J Neurochem; 2013 May; 125(3):465-72. PubMed ID: 23240999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]